Sutro Biopharma (STRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $163.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sutro Biopharma (STRO) Earnings: Report Dates and Results
Sutro Biopharma (STRO) is expected to report earnings on Mar 22, 2027. In the quarter ended Sep 30, 2026, Sutro Biopharma reported EPS of -$1.90, below the -$1.88 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
STRO has an expected report date of Mar 22, 2027.
Earnings History
Of the 31 quarters below that had an estimate, STRO beat 16 and missed 15. Revenue for the quarter ended Sep 30, 2026 was $9.10M, down 6.1% from $9.69M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.90 | -$1.88 | -$2.38 - -$1.45 | -1.06% | Miss | N/A | 3 | 1 up, 0 down | Nov 12, 2026 | $9.10M |
| Jun 30, 2026 | -$2.33 | -$2.04 | N/A | -14.22% | Miss | N/A | 3 | 0 up, 0 down | Aug 12, 2026 | $9.84M |
| Mar 31, 2026 | -$2.94 | -$3.21 | -$3.65 - -$2.78 | +8.41% | Beat | N/A | 2 | 0 up, 0 down | May 14, 2026 | $14.52M |
| Dec 31, 2025 | -$5.45 | -$0.43 | -$0.46 - -$0.43 | N/A | N/A | N/A | 2 | 1 up, 0 down | Mar 23, 2026 | $11.65M |
| Sep 30, 2025 | -$5.57 | -$3.55 | N/A | -56.90% | Miss | N/A | 1 | 1 up, 0 down | Nov 6, 2025 | $9.69M |
| Jun 30, 2025 | -$0.14 | -$0.39 | N/A | +64.10% | Beat | N/A | 1 | 0 up, 0 down | Aug 7, 2025 | $63.74M |
| Mar 31, 2025 | -$8.02 | -$9.20 | N/A | +12.83% | Beat | N/A | N/A | 0 up, 0 down | May 8, 2025 | $17.40M |
| Dec 31, 2024 | -$0.63 | -$0.96 | -$1.13 - -$0.78 | +33.70% | Beat | -221.8% | 2 | 0 up, 2 down | Mar 13, 2025 | $14.81M |
| Sep 30, 2024 | -$4.98 | -$7.35 | -$8.90 - -$5.40 | +32.24% | Beat | N/A | 11 | 0 up, 0 down | Nov 13, 2024 | $8.52M |
| Jun 30, 2024 | -$5.61 | -$9.00 | -$10.40 - -$0.90 | +37.67% | Beat | N/A | 10 | 0 up, 0 down | Aug 13, 2024 | $25.71M |
| Mar 31, 2024 | -$8.90 | -$9.95 | -$10.90 - -$7.20 | +10.55% | Beat | N/A | 10 | 0 up, 0 down | May 13, 2024 | $13.01M |
| Dec 31, 2023 | $0.52 | -$0.82 | -$0.94 - -$0.71 | +163.41% | Beat | N/A | 9 | 0 up, 0 down | Mar 25, 2024 | $113.72M |
| Sep 30, 2023 | -$8.10 | -$7.15 | -$8.40 - -$5.60 | -13.29% | Miss | N/A | 10 | 0 up, 0 down | Nov 13, 2023 | $16.92M |
| Jun 30, 2023 | -$7.69 | -$6.87 | -$8.40 - -$6.30 | -11.94% | Miss | N/A | 8 | 0 up, 0 down | Aug 10, 2023 | $10.41M |
| Mar 31, 2023 | -$0.85 | -$0.81 | -$0.99 - -$0.68 | -4.94% | Miss | N/A | 7 | 0 up, 0 down | May 15, 2023 | $12.67M |
| Dec 31, 2022 | -$8.18 | -$6.32 | -$8.40 - -$3.30 | -29.43% | Miss | N/A | 8 | 0 up, 1 down | Mar 30, 2023 | $8.63M |
| Sep 30, 2022 | -$3.70 | $0.12 | N/A | N/A | N/A | N/A | 6 | 0 up, 0 down | Nov 8, 2022 | $25.15M |
| Jun 30, 2022 | -$5.50 | -$7.70 | -$8.80 - $10.80 | +28.57% | Beat | N/A | 7 | 1 up, 0 down | Aug 8, 2022 | $28.10M |
| Mar 31, 2022 | -$8.40 | -$7.37 | -$9.50 - -$5.40 | -13.98% | Miss | N/A | 8 | 0 up, 0 down | May 9, 2022 | $5.90M |
| Dec 31, 2021 | -$0.83 | -$0.69 | -$0.94 - -$0.42 | -20.29% | Miss | N/A | 8 | N/A | Feb 28, 2022 | $10.65M |
| Sep 30, 2021 | -$6.70 | -$4.80 | N/A | -39.58% | Miss | N/A | 8 | 0 up, 0 down | Nov 10, 2021 | $8.52M |
| Jun 30, 2021 | -$1.30 | -$4.00 | -$5.60 - -$2.40 | +67.50% | Beat | N/A | 8 | N/A | Aug 9, 2021 | $28.05M |
| Mar 31, 2021 | -$4.28 | -$6.00 | -$7.30 - -$4.80 | +28.67% | Beat | N/A | 7 | N/A | May 7, 2021 | $14.66M |
| Dec 31, 2020 | -$1.48 | -$0.57 | -$0.77 - -$0.33 | -159.65% | Miss | N/A | 8 | N/A | Mar 18, 2021 | $8.28M |
| Sep 30, 2020 | -$3.34 | -$5.00 | -$7.00 - -$2.60 | +33.20% | Beat | N/A | 7 | N/A | Nov 5, 2020 | $17.82M |
| Jun 30, 2020 | -$5.97 | -$5.74 | -$8.50 - -$4.70 | -4.01% | Miss | N/A | 8 | N/A | Aug 6, 2020 | $9.47M |
| Mar 31, 2020 | -$8.40 | -$5.68 | -$9.40 - -$4.90 | -47.89% | Miss | N/A | 7 | N/A | May 11, 2020 | $7.15M |
| Dec 31, 2019 | -$0.64 | -$0.69 | -$0.83 - -$0.56 | +7.25% | Beat | N/A | 8 | N/A | Mar 16, 2020 | $11.30M |
| Sep 30, 2019 | -$5.60 | -$6.17 | -$7.50 - -$4.30 | +9.24% | Beat | N/A | 7 | N/A | Nov 8, 2019 | $12.28M |
| Jun 30, 2019 | -$6.00 | -$6.01 | -$8.00 - -$5.70 | +0.17% | Beat | N/A | 4 | N/A | Aug 14, 2019 | $10.53M |
| Mar 31, 2019 | -$6.20 | -$6.10 | -$7.00 - -$5.50 | -1.64% | Miss | N/A | 4 | N/A | Apr 1, 2019 | $8.63M |
| Dec 31, 2018 | -$0.26 | -$0.63 | -$0.73 - -$0.53 | +58.73% | Beat | N/A | 4 | N/A | Dec 31, 2018 | $19.09M |
| Sep 30, 2018 | -$4.34 | $19.70 | N/A | -122.03% | Miss | N/A | 4 | N/A | Nov 14, 2018 | $7.84M |
| Jun 30, 2018 | -$1.37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 26, 2018 | $5.70M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$19.18, after -$20.12 the year before. It was -$5.97 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$19.18 | N/A |
| Dec 31, 2024 | -$20.12 | N/A |
| Dec 31, 2023 | -$16.12 | N/A |
| Dec 31, 2022 | -$25.78 | N/A |
| Dec 31, 2021 | -$13.11 | N/A |
| Dec 31, 2020 | -$19.19 | N/A |
| Dec 31, 2019 | -$18.44 | N/A |
| Dec 31, 2018 | -$5.97 | N/A |
Frequently Asked Questions About STRO
When is Sutro Biopharma's next earnings date?
Sutro Biopharma's next earnings report is expected for Mar 22, 2027.
Did STRO beat earnings estimates last quarter?
No. Sutro Biopharma reported EPS of -$1.90 for the quarter ended Sep 30, 2026, below the -$1.88 estimate by 1.06%.
What EPS do analysts expect from STRO next quarter?
The consensus EPS estimate for Sutro Biopharma for the quarter ending Dec 31, 2026 is -$1.72 from 16 analysts, with estimates from -$2.70 to -$0.95.
How often does STRO beat earnings estimates?
Sutro Biopharma beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +9.89%.
STRO pages: Overview, Earnings, Forecast, Financials, Competitors